Tempo Therapeutics, a San Diego, CA-based innovator in tissue engineering and regenerative medicine, raised $12M in Series A funding.
The round was led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC). In conjunction with the financing, Steven Sands of Galaxy Partners and a representative from JJDC will join the board.
Led by Westbrook Weaver, Founder and CEO, Tempo Therapeutics is a clinical-stage technology company that advances tissue engineering. Tempo leverages its patented microporous-annealed-particle (MAP) technology platform to improve immunomodulation and material science to transform the landscape of medical technology by developing new synthetic biomaterials for use in a variety of surgical reconstruction and therapeutic regenerative applications.
With this financing, the company is entering into clinical trials of surgical scaffolds based on MAP technology. As the sole developer of MAP technology-based tissue scaffolds, Tempo aims to reach critical development milestones by establishing the safety and effectiveness of its two lead products: TT101, for complex surgical sites with exposed bone, tendon, or fascia; and TT108 for fascial incision site reinforcement.
The Microporous Annealed Particle (MAP) technology is a first-in-class volumetric injectable porous scaffolding for regenerative medicine. The MAP technology enables Tempo to repurpose established hydrogel polymer components with safety profiles by assembling them into a hyper-porous, flowable scaffold format. MAP based products immediately allow tissue ingrowth and integration upon application. Tissue implants using MAP technology are able to evade the typical inflammatory and scar-forming Foreign Body Response (FBR) and instead promote a regenerative immune response that leads to accelerated formation of vascularized tissue volume.
Commenting on the news, Westbrook Weaver said: “The successful completion of our Series A financing is a testament to the confidence placed in our vision by our investors. Together, we are poised to unlock new horizons in tissue engineering and redefine what is possible in regenerative medicine.”
FinSMEs
20/03/2024